Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company pioneering next-generation mental health therapeutics, announced the closing of its previously disclosed registered direct offering for gross proceeds of approximately US$175 million. The financing included 22,277,750 common shares and 4,605,500 pre-funded warrants priced at US$6.51 each, with participation from leading investors including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, and Adage Capital Partners. Each unit includes 0.35 of a warrant exercisable at US$8.14 per share before June 30, 2027, or earlier under specified conditions. Jefferies, TD Cowen, and Cantor acted as joint lead placement agents, with Bloom Burton Securities Inc. serving as placement agent.
The successful closure of this substantial offering underscores the market's confidence in Cybin's pipeline, particularly CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for the adjunctive treatment of major depressive disorder (MDD). CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address a significant unmet need in mental health. Additionally, Cybin is developing CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder, and maintains a research pipeline of investigational 5-HT-receptor focused compounds.
The capital raised will likely accelerate Cybin's clinical programs and operational expansion. The company, founded in 2019 and operational in Canada, the United States, the United Kingdom and Ireland, aims to revolutionize mental healthcare by developing new treatment options for conditions with large unmet needs. The involvement of top-tier healthcare investors such as Venrock and OrbiMed signals strong institutional backing for Cybin's approach.
As noted in the press release, the full details are available at https://ibn.fm/psED0. This financing event is a significant milestone for Cybin, potentially enabling it to advance its lead candidates through late-stage trials and toward regulatory submission. The company's focus on deuterated compounds may offer advantages in efficacy and safety over existing treatments, addressing the large unmet need for people suffering from mental health conditions.
For more information about Cybin and its latest updates, visit the company's newsroom at https://ibn.fm/CYBN. This announcement was disseminated by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides wire-grade press release syndication and enhanced corporate communications solutions. InvestorWire is based in Austin, Texas, and can be reached at 512.354.7000 or through its website at https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website.
